HeartBeam's Portable ECG Device Shows Promise in Identifying Heart Attack Risk, Study Finds
A peer-reviewed study published in JACC: Advances demonstrates that HeartBeam's credit card-sized ECG device, combined with a risk prediction algorithm, can accurately identify heart attack risk in chest pain patients, with accuracy rising to 92.9% when a baseline ECG is available.
HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating its credit card-sized ECG device can accurately identify heart attack risk in patients presenting with chest pain. The study, a proof-of-concept analysis, evaluated 184 patients and found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. When a personal, symptom-free baseline ECG was available for comparison, the AUC rose to 92.9%.
These results are significant because they support heart attack detection as a future indication for the HeartBeam System and advance the company's broader clinical program. The ability to accurately assess heart attack risk in a portable, credit card-sized device could have major implications for emergency medicine and remote patient monitoring. Currently, chest pain is one of the most common reasons for emergency department visits, and rapid risk stratification is critical for timely treatment. A device that can be used outside of a medical facility to provide actionable insights could reduce unnecessary hospital admissions and expedite care for those in need.
HeartBeam's platform technology is designed to be the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing them into a 12-lead ECG. This allows for portable use wherever the patient is, delivering actionable heart intelligence to physicians. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology.
The implications of this study are far-reaching. If validated in larger trials, the HeartBeam System could become a standard tool for early heart attack detection, potentially saving lives by enabling faster diagnosis and treatment. For investors, the study underscores the company's progress in expanding its indications beyond arrhythmia assessment to acute cardiac conditions. The full press release is available at https://ibn.fm/ainxV. More information about HeartBeam and its cleared indications for use can be found at https://www.heartbeam.com/indications.